Nasdaq Biotechnology Ishares ETF (IBB)
$132.83 0.00 (0.00%)
19:49 EDT IBB Stock Quote Delayed 30 Minutes
Previous Close $132.83
Market Cap 11.55B
PE Ratio -
Volume (Avg. Vol.)
Day's Range 132.83 - 132.83
52-Week Range 92.15 - 146.53
Dividend & Yield 0.31 (0.24%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
Amid ongoing industry consolidation, attractive valuations and a strong broad market, catalysts are in place for more upside for biotech ETFs.
The charts for the IBB ETF in multiple time frames suggest the recent rally in biotech stocks is overdone for the time being.
By Ken Trester
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
Biotech ETFs lagged in 2018, but that doesn't mean there aren't healthcare funds to consider for 2019.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
PFE is a proven survivor stock and it now sits on a potential long term technical breakout. Go long its potential with confidence.
Large-cap biotech stocks as a group rallied along with the broader stock market on Wednesday. While so doing, some big names like AMGN stock broke past key near-term technical resistance.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
Both biotech stocks and big pharma stocks involve a different mindset. Treat biotech stocks like options and big pharma stocks like ETFs.
We saw another strong rally on Thursday in the broader U.S. stock market. That's got us eyeing a few new top stock trades for Friday.
TEVA stock has potential that is purely technical. Teva Pharmaceutical is showing a breakout that would send it 25% higher from here, so now is the time to go long.
These biotech and pharmaceutical stocks are soaring insanely high right now. Here's what investors should know about each of these hot stocks to buy.
CELG stock continues to notably lag some of its peers in the biotechnology group, but this could soon change and set up a juicy Celgene trade.
A 50% pop on speculation is as good a reason to short JUNO stock as any. This is how you should play Juno Therapeutics now.